Targeting cancer therapy in mice by use of newly developed immunoliposomes bearing adriamycin

Masaki Hirota, Kiyoyasu Fukushima, Kazuhito Hiratani, Junichi Kadota, Kenji Kawano, Mikio Oka, Akimitsu Tomonaga, Kohei Hara, Toshinori Sato, Junzo Sunamoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Polysaccharide-coated liposomes have been developed to improve the stability of conventional liposomes against biochemical and physicochemical stimuli. Pullulan (MW 5 × 104) was used as the polysaccharide. the mouse IgM monoclonal antibody (CSLEX 1) recognizes a sialosylated Lex, which is a tumor-specific antigen in athymic mice. the IgM antibody was reduced with cysteine to obtain the subunit (IgMs) that remained biologically active. the IgMs was accumulated in an antigen-positive tumor in vivo. Subsequently, it was conjugated with the pullulan-coated liposome to form an immunoliposome. Tissue distribution studies demonstrated that immunoliposomes were more efficiently targeted to an implanted tumor than to the polysaccharide-coated liposomes. This is accompanied by a drastic decrease in liver uptake of the immunoliposomes. Furthermore, adriamycin-encapsulated immunoliposomes in-hibited the growth of the implanted tumor more effectively than did the simple pulluian-coated liposomes.

Original languageEnglish
Pages (from-to)15-33
Number of pages19
JournalJournal of Liposome Research
Volume1
Issue number1
DOIs
Publication statusPublished - 1988 Jan 1
Externally publishedYes

Fingerprint

Liposomes
Doxorubicin
Polysaccharides
Neoplasm Antigens
Neoplasms
Immunoglobulin M
Therapeutics
Tissue Distribution
Nude Mice
Cysteine
Monoclonal Antibodies
Antibodies
Liver
Growth
pullulan

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Hirota, M., Fukushima, K., Hiratani, K., Kadota, J., Kawano, K., Oka, M., ... Sunamoto, J. (1988). Targeting cancer therapy in mice by use of newly developed immunoliposomes bearing adriamycin. Journal of Liposome Research, 1(1), 15-33. https://doi.org/10.3109/08982108809035980

Targeting cancer therapy in mice by use of newly developed immunoliposomes bearing adriamycin. / Hirota, Masaki; Fukushima, Kiyoyasu; Hiratani, Kazuhito; Kadota, Junichi; Kawano, Kenji; Oka, Mikio; Tomonaga, Akimitsu; Hara, Kohei; Sato, Toshinori; Sunamoto, Junzo.

In: Journal of Liposome Research, Vol. 1, No. 1, 01.01.1988, p. 15-33.

Research output: Contribution to journalArticle

Hirota, M, Fukushima, K, Hiratani, K, Kadota, J, Kawano, K, Oka, M, Tomonaga, A, Hara, K, Sato, T & Sunamoto, J 1988, 'Targeting cancer therapy in mice by use of newly developed immunoliposomes bearing adriamycin', Journal of Liposome Research, vol. 1, no. 1, pp. 15-33. https://doi.org/10.3109/08982108809035980
Hirota, Masaki ; Fukushima, Kiyoyasu ; Hiratani, Kazuhito ; Kadota, Junichi ; Kawano, Kenji ; Oka, Mikio ; Tomonaga, Akimitsu ; Hara, Kohei ; Sato, Toshinori ; Sunamoto, Junzo. / Targeting cancer therapy in mice by use of newly developed immunoliposomes bearing adriamycin. In: Journal of Liposome Research. 1988 ; Vol. 1, No. 1. pp. 15-33.
@article{b86106010b2944a5858da24061fd3b81,
title = "Targeting cancer therapy in mice by use of newly developed immunoliposomes bearing adriamycin",
abstract = "Polysaccharide-coated liposomes have been developed to improve the stability of conventional liposomes against biochemical and physicochemical stimuli. Pullulan (MW 5 × 104) was used as the polysaccharide. the mouse IgM monoclonal antibody (CSLEX 1) recognizes a sialosylated Lex, which is a tumor-specific antigen in athymic mice. the IgM antibody was reduced with cysteine to obtain the subunit (IgMs) that remained biologically active. the IgMs was accumulated in an antigen-positive tumor in vivo. Subsequently, it was conjugated with the pullulan-coated liposome to form an immunoliposome. Tissue distribution studies demonstrated that immunoliposomes were more efficiently targeted to an implanted tumor than to the polysaccharide-coated liposomes. This is accompanied by a drastic decrease in liver uptake of the immunoliposomes. Furthermore, adriamycin-encapsulated immunoliposomes in-hibited the growth of the implanted tumor more effectively than did the simple pulluian-coated liposomes.",
author = "Masaki Hirota and Kiyoyasu Fukushima and Kazuhito Hiratani and Junichi Kadota and Kenji Kawano and Mikio Oka and Akimitsu Tomonaga and Kohei Hara and Toshinori Sato and Junzo Sunamoto",
year = "1988",
month = "1",
day = "1",
doi = "10.3109/08982108809035980",
language = "English",
volume = "1",
pages = "15--33",
journal = "Journal of Liposome Research",
issn = "0898-2104",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Targeting cancer therapy in mice by use of newly developed immunoliposomes bearing adriamycin

AU - Hirota, Masaki

AU - Fukushima, Kiyoyasu

AU - Hiratani, Kazuhito

AU - Kadota, Junichi

AU - Kawano, Kenji

AU - Oka, Mikio

AU - Tomonaga, Akimitsu

AU - Hara, Kohei

AU - Sato, Toshinori

AU - Sunamoto, Junzo

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Polysaccharide-coated liposomes have been developed to improve the stability of conventional liposomes against biochemical and physicochemical stimuli. Pullulan (MW 5 × 104) was used as the polysaccharide. the mouse IgM monoclonal antibody (CSLEX 1) recognizes a sialosylated Lex, which is a tumor-specific antigen in athymic mice. the IgM antibody was reduced with cysteine to obtain the subunit (IgMs) that remained biologically active. the IgMs was accumulated in an antigen-positive tumor in vivo. Subsequently, it was conjugated with the pullulan-coated liposome to form an immunoliposome. Tissue distribution studies demonstrated that immunoliposomes were more efficiently targeted to an implanted tumor than to the polysaccharide-coated liposomes. This is accompanied by a drastic decrease in liver uptake of the immunoliposomes. Furthermore, adriamycin-encapsulated immunoliposomes in-hibited the growth of the implanted tumor more effectively than did the simple pulluian-coated liposomes.

AB - Polysaccharide-coated liposomes have been developed to improve the stability of conventional liposomes against biochemical and physicochemical stimuli. Pullulan (MW 5 × 104) was used as the polysaccharide. the mouse IgM monoclonal antibody (CSLEX 1) recognizes a sialosylated Lex, which is a tumor-specific antigen in athymic mice. the IgM antibody was reduced with cysteine to obtain the subunit (IgMs) that remained biologically active. the IgMs was accumulated in an antigen-positive tumor in vivo. Subsequently, it was conjugated with the pullulan-coated liposome to form an immunoliposome. Tissue distribution studies demonstrated that immunoliposomes were more efficiently targeted to an implanted tumor than to the polysaccharide-coated liposomes. This is accompanied by a drastic decrease in liver uptake of the immunoliposomes. Furthermore, adriamycin-encapsulated immunoliposomes in-hibited the growth of the implanted tumor more effectively than did the simple pulluian-coated liposomes.

UR - http://www.scopus.com/inward/record.url?scp=0024212630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024212630&partnerID=8YFLogxK

U2 - 10.3109/08982108809035980

DO - 10.3109/08982108809035980

M3 - Article

AN - SCOPUS:0024212630

VL - 1

SP - 15

EP - 33

JO - Journal of Liposome Research

JF - Journal of Liposome Research

SN - 0898-2104

IS - 1

ER -